Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients

European Respiratory Journal

Volumn 45, Issue 6, 2015, Pages 1642-1652

  Lee, Nelson ^a,b   Leo, Yee Sin ^c   Cao, Bin ^d   Chan, Paul K S ^b   Kyaw, W M ^c   Uyeki, Timothy M ^e   Tam, Wilson W S ^b   Cheung, Catherine S K ^a   Yung, Irene M H ^a   Li, Hui ^d   Gu, Li ^d   Liu, Yingmei ^d   Liu, Zhenjia ^d   Qu, Jiuxin ^d   Hui, David S C ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR; CYCLOPENTANE DERIVATIVE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIALIDASE;

ADULT; AGED; ARTICLE; BACTERIAL SUPERINFECTION; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PANDEMIC INFLUENZA; PNEUMONIA; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SEASONAL INFLUENZA; SUPERINFECTION; SURVIVAL; ANTAGONISTS AND INHIBITORS; CHINA; HONG KONG; INFLUENZA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMONIA, BACTERIAL; PROPORTIONAL HAZARDS MODEL; PROTECTION; RESPIRATORY INSUFFICIENCY; RISK FACTOR; SINGAPORE; VERY ELDERLY; YOUNG ADULT;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; BEIJING; COHORT STUDIES; CYCLOPENTANES; ENZYME INHIBITORS; FEMALE; GUANIDINES; HONG KONG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEURAMINIDASE; OSELTAMIVIR; PNEUMONIA, BACTERIAL; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTECTIVE FACTORS; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; SINGAPORE; SUPERINFECTION; YOUNG ADULT; ZANAMIVIR;

EID: 84930387811     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00169714     Document Type: Article

References (44)

1. World Health Organization (WHO). Influenza. www.who.int/influenza/en/ Date last accessed: September 1, 2014.
2. Leo YS, Lye DC, Chow A. Influenza in the tropics. Lancet Infect Dis 2009; 9: 457-458.
3. Lee N, Ison MG. Diagnosis, management and outcomes of adults hospitalized with influenza. Antivir Ther 2012; 17: 143-157.
4. Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012; 12: 687-695.
5. Lee N, Chan PK, Lui GC, et al. Complications and outcomes of pandemic 2009 influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? J Infect Dis 2011; 203: 1739-1747.
6. Lee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalised with severe influenza. Thorax 2010; 65: 510-515.
7. Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 2012; 156: 512-524.
8. Hui DS, Lee N, Chan PK. Adjunctive therapies and immunomodulatory agents in the management of severe influenza. Antiviral Res 2013; 98: 410-416.
9. Leo YS, Lye DC, Barkham T, et al. Pandemic (H1N1) 2009 surveillance and prevalence of seasonal influenza, Singapore. Emerg Infect Dis 2010; 16: 103-105.
10. Win MK, Chen MI, Barkham T, et al. Influenza disease burden in adults by subtypes following the initial epidemic of pandemic H1N1 in Singapore. Influenza Other Respir Viruses 2011; 5: e563-e567.
11. Yang SQ, Qu JX, Wang C, et al. Influenza pneumonia among adolescents and adults: a concurrent comparison between influenza A (H1N1) pdm09 and A (H3N2) in the post-pandemic period. Clin Respir J 2014; 8: 185-191.
12. Bai L, Gu L, Cao B, et al. Clinical features of pneumonia caused by 2009 influenza A(H1N1) virus in Beijing, China. Chest 2011; 139: 1156-1164.
13. Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60: 1-24.
14. Zhong NS, Li YM, Yang ZF, et al. Chinese guidelines for diagnosis and treatment of influenza (2011). J Thorac Dis 2011; 3: 274-289.
15. Xu R, Luo Y, Chambers C. Assessing the effect of vaccine on spontaneous abortion using time-dependent covariates Cox models. Pharmacoepidemiol Drug Saf 2012; 21: 844-850.
16. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2: 395-404.
17. Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A (H5N1) infections: analysis of a Global Patient Registry. J Infect Dis 2010; 202: 1154-1160.
18. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200: 492-500.
19. Ling LM, Chow AL, Lye DC, et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis 2010; 50: 963-969.
20. Chan PK, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis 2012; 206: 1359-1366.
21. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55: 1198-1204.
22. Yu H, Feng Z, Uyeki TM, et al. Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. Clin Infect Dis 2011; 52: 457-465.
23. Fry AM, Goswami D, Nahar K, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis 2014; 14: 109-118.
24. Yang SG, Cao B, Liang LR, et al. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS One 2012; 7: e29652.
25. Higuera Iglesias AL, Kudo K, Manabe T, et al. Reducing occurrence and severity of pneumonia due to pandemic H1N1 2009 by early oseltamivir administration: a retrospective study in Mexico. PLoS One 2011; 6: e21838.
26. Garg S, Chaves SS, Pérez A, et al. Reduced influenza antiviral treatment among children and adults hospitalized with laboratory-confirmed influenza infection in the year after the 2009 pandemic. Clin Infect Dis 2012; 55: e18-e21.
27. Uyeki TM. Preventing and controlling influenza with available interventions. N Engl J Med 2014; 370: 789-791.
28. McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol 2014; 12: 252-262.
29. Rebmann T, Greene LR. Preventing ventilator-associated pneumonia: an executive summary of the Association for Professionals in Infection Control and Epidemiology, Inc, Elimination Guide. Am J Infect Control 2010; 38: 647-649.
30. Kim SH, Hong SB, Yun SC, et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011; 183: 1207-1214.
31. Han K, Ma H, An X, et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin Infect Dis 2011; 53: 326-333.
32. Lee N, Hui DS. Dexamethasone in community-acquired pneumonia. Lancet 2011; 378: 979-980.
33. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013; 99: 417-435.
34. Mortensen EM, Nakashima B, Cornell J, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis 2012; 55: 1466-1473.
35. Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012; 205: 13-19.
36. Walsh EE. Statins and influenza: can we move forward? J Infect Dis 2012; 205: 1-3.
37. The National Heart, Lung, and Blood Institute ARDS Clinical Trials Network, Truwit JD, Bernard GR, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 2014; 370: 2191-2200.
38. Kruger P, Bailey M, Bellomo R, et al. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 2013; 187: 743-750.
39. Belser JA, Szretter KJ, Katz JM, et al. Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice. Virology 2013; 439: 42-46.
40. Leonardi-Bee J, Venkatesan S, Muthuri SG, et al. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. Lancet Respir Med 2014; 2: e10-e12.
41. Chan MC, Lee N, Lui GC, et al. Comparisons of oseltamivir-resistant (H275Y) and concurrent oseltamivir-susceptible seasonal influenza A(H1N1) virus infections in hospitalized adults, 2008-2009. Influenza Other Respir Viruses 2013; 7: 235-239.
42. Wu S, Yang P, Li H, et al. Influenza vaccination coverage rates among adults before and after the 2009 influenza pandemic and the reasons for non-vaccination in Beijing, China: a cross-sectional study. BMC Public Health 2013; 13: 636.
43. Chor JS, Ngai KL, Goggins WB, et al. Willingness of Hong Kong healthcare workers to accept pre-pandemic influenza vaccination at different WHO alert levels: two questionnaire surveys. BMJ 2009; 339: b3391.
44. Zhang YH, Zhao Y, Li N, et al. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat Commun 2013; 4: 1418.